Trials / Unknown
UnknownNCT04278820
A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)
A Phase IIa, Randomized, Double-blind, Placebo-controlled Study of TQA3526 in the Treatment of Naive or Previously Treated PBC Patients
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
TQA3526 is a modified bile acid and FXR agonist. FXR is a key regulator of bile acid synthesis and transport. Bile acids are used by the body to help with digestion. It is hypothesized that regular treatment with TQA3526 will improve liver function in persons with Primary Biliary Cirrhosis (PBC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQA3526 | Tablet(s) administered orally once daily |
| DRUG | Placebo to match TQA3526 | Tablet(s) administered orally once daily |
Timeline
- Start date
- 2020-03-20
- Primary completion
- 2022-11-30
- Completion
- 2022-11-30
- First posted
- 2020-02-20
- Last updated
- 2020-02-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04278820. Inclusion in this directory is not an endorsement.